IRX4204 shows promise in repairing myelin and restoring function in Multiple Sclerosis model.
Read more
FDA accepts Arbor's IND for ABO-101, a gene editing therapy for Primary Hyperoxaluria Type 1.
Read more
OraSure Technologies acquires Sherlock Biosciences to enhance rapid STI diagnostics with molecular self-tests.
Read more
Silexion partners with Evonik to develop advanced siRNA formulation for KRAS-driven cancers.
Read more
ExeGi Pharma's EXE-346 shows safety and reduces stool frequency in Phase 1b trial for ileal pouch-anal anastomosis patients.
Read more
TAE Life Sciences and CNAO partner to advance Boron Neutron Capture Therapy for metastatic cancers.
Read more
HKBU's aptamer for X-linked Hypophosphatemia receives Orphan Drug and Rare Pediatric Disease Designations from U.S. FDA.
Read more
Fierce Biotech highlights top 2024 trends, including ADC deals, cell therapy shifts, and biotech bankruptcies.
Read more
ÅŒURA secures $200M in Series D funding to expand smart ring offerings and global presence.
Read more
Actuate Therapeutics reports positive Phase 2 results for elraglusib in metastatic pancreatic cancer, showing improved survival rates.
Read more
EMA validates Cytokinetics' application for aficamten to treat obstructive Hypertrophic Cardiomyopathy.
Read more
EYLEA HD meets Phase 3 trial endpoint, improving vision with extended dosing for Macular Edema following Retinal Vein Occlusion.
Read more
FDA grants Priority Review to Nuvation Bio's taletrectinib for advanced ROS1-positive Non-Small Cell Lung Cancer.
Read more
Kynexis reports positive Phase 1 results for KYN-5356, targeting Cognitive Impairment in Schizophrenia.
Read more
FDA approves first generic GLP-1 injection for Type 2 Diabetes, enhancing patient access and affordability.
Read more
Orexo partners with Abera to develop nasal powder vaccines using AmorphOX technology for enhanced stability and efficacy.
Read more
Teva and Sanofi's Duvakitug shows promising Phase 2b results for Ulcerative Colitis and Crohn's Disease, advancing to Phase 3 trials.
Read more
FDA approves GEMTESA for Overactive Bladder in men with Benign Prostatic Hyperplasia.
Read more
FDA approves Ensartinib for ALK-positive metastatic Non-Small Cell Lung Cancer, offering a new first-line treatment option.
Read more
Assembly Bio secures $30.1M from Gilead to advance Hepatitis D virus candidate ABI-6250 development.
Read more
Novo Holdings completes $16.5 billion acquisition of Catalent, enhancing pharmaceutical development and supply capabilities.
Read more
Terray partners with Gilead to leverage AI for small molecule drug discovery using the tNova platform.
Read more
Ultragenyx doses first patient in Phase 3 trial of GTX-102 for Angelman Syndrome.
Read more
CD40 targeted therapies expected to gain first approval by 2027, with over 20 therapies in clinical trials.
Read more
Gene-edited pig kidney transplant offers new hope for end-stage kidney disease patients.
Read more
